Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
IGCthis companyIGC Pharma, Inc.	$0.20	-3.64×	4.08×	21.08×	-3.96×	-225.3%	29.7%	-860.3%	-552.1%	-107.0%	-144.8%	-24.4%	0.15×	-0.11×	0×	0.4×	0.0%	1	-18.6	1	C-
ANTXAN2 Therapeutics, Inc.	$4.04	-0.98×	0.65×	0×	-0.41×	-86.4%	0.0%	0.0%	0.0%	-66.3%	-71.6%	-86.6%	0×	0.57×	0×	6.87×	0.0%	1	12.25	1	C-
BOLDBoundless Bio, Inc.	$2.45	-0.46×	0.27×	0×	-1.02×	-159.7%	0.0%	0.0%	0.0%	-59.0%	-43.0%	-175.9%	0.5×	-0.55×	0×	8.74×	0.0%	1	-3.14	2	C
INTSIntensity Therapeutics, Inc.	$2.93	-1.2×	1.17×	0×	-0.18×	143.3%	0.0%	0.0%	0.0%	-97.7%	-99.9%	-66.3%	0.01×	1.02×	0×	5.92×	0.0%	2	-10.06	3	B
NTRBNutriband Inc.	$5.64	-1.86×	8.35×	27.38×	-6.42×	-123.8%	27.8%	-408.4%	-404.1%	-123.2%	-120.1%	-9.2%	0.04×	0.54×	-369.11×	6.36×	0.0%	3	34.78	1	C-
NXTCNextCure, Inc.	$5.42	-0.72×	1.15×	0×	-0.36×	17.9%	0.0%	0.0%	0.0%	-159.8%	-141.8%	-123.0%	0.15×	0.39×	0×	4.14×	0.0%	1	-32.41	2	B-
Peer median	—	-0.98×	1.15×	0×	-0.41×	-86.4%	0.0%	0.0%	0.0%	-97.7%	-99.9%	-86.6%	0.04×	0.54×	0×	6.36×	0.0%	1	-3.14	2	—